Florian Rosar - Publications

Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 09, 2026

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: March 30, 2026

Automated PROMISE V2 Scoring from PSMA PET/CT Reports Using Large Language Models: A Comparative Evaluation of Prompt Design and Model Performance.

Journal: Current oncology (Toronto, Ont.)

Published: March 27, 2026

Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 24, 2026

Auger Emitting [161Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal Carcinomatosis.

Journal: Nuclear medicine and molecular imaging

Published: October 15, 2025

Diagnosis of Extra-Skeletal Ewing Sarcoma in an 11-Year-Old Child with Large Thoracic Mass revealed by [18F]FDG PET/CT.

Journal: Nuclear medicine and molecular imaging

Published: September 30, 2025

Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression.

Journal: EJNMMI research

Published: September 26, 2025

Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 12, 2025

Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617.

Journal: Clinical nuclear medicine

Published: August 19, 2025

Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience.

Journal: EJNMMI research

Published: July 18, 2025

Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapy.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: July 03, 2025

The Influence of Hyperthyroid Metabolic Status on the Coagulation and Fibrinolysis System and the Risk of Thrombosis: A Prospective Cohort Study.

Journal: Biomedicines

Published: June 06, 2025